Precision Medicine Group Executive and Leadership Team

Margaret Keegan, the Chief Executive Officer at Precision Medicine Group, directs the overarching corporate strategy and global operational vision. Keegan oversees the integration of clinical research, laboratory services, and data science to support pharmaceutical clients throughout the drug development lifecycle. By aligning internal resources with the evolving needs of the biotech sector, the Chief Executive Officer ensures consistent delivery of high-quality scientific outcomes across North America, Europe, and Asia-Pacific. This leadership role involves constant collaboration with the board to drive long-term growth and market expansion. Margaret Keegan maintains a focus on operational excellence, ensuring that the company remains a leader in life sciences services. Through the optimization of cross-functional workflows, the Chief Executive Officer fosters an environment of innovation, ultimately securing the company's position as a critical partner for complex drug development programs.

Mark Clein, the Co-Founder & Chief Executive Officer at Precision Medicine Group, architects the foundational business model and long-term strategic direction. Clein drives the expansion of the company's two primary platforms, Precision for Medicine and Precision AQ, to ensure comprehensive support for drug development and commercialization. The Co-Founder & Chief Executive Officer manages high-level partnerships with global biotech firms, focusing on the delivery of specialized market access and medical communication services. By overseeing the strategic alignment of these diverse service offerings, Mark Clein ensures that the organization meets the complex demands of the life sciences industry. This leadership role involves identifying new market opportunities and scaling operations to maintain a competitive edge. Through the continuous refinement of the corporate mission, the Co-Founder & Chief Executive Officer sustains the company's reputation for excellence in clinical research and commercial strategy.

Wendy Shusko, the Chief Financial Officer, Precision AQ at Precision Medicine Group, manages the financial health and fiscal strategy for the market access and medical communications division. Shusko oversees budgeting, financial reporting, and resource allocation to ensure the profitability of commercialization services. The Chief Financial Officer, Precision AQ drives financial planning initiatives that support the growth of payer insights and medical communications platforms. By analyzing market trends and operational costs, Shusko ensures that the division maintains a strong competitive position within the global life sciences landscape. This leadership role involves close coordination with executive leadership to align financial goals with the broader corporate mission. Wendy Shusko executes rigorous financial oversight, ensuring that the division possesses the necessary capital to invest in innovative service offerings. Through disciplined fiscal management, the Chief Financial Officer, Precision AQ supports the long-term sustainability of the company's commercialization efforts.

Michael Winston, the Translational Sciences Chief Operating Officer & Chief Financial Officer at Precision Medicine Group, directs the operational and financial performance of the translational sciences division. Winston oversees the integration of laboratory services and genomics research, ensuring that scientific operations remain both efficient and financially viable. The Translational Sciences Chief Operating Officer & Chief Financial Officer manages the allocation of capital toward advanced research equipment and specialized talent. By balancing scientific innovation with fiscal responsibility, Winston ensures that the division delivers high-value insights to biotech clients. This leadership role involves monitoring project profitability and optimizing the cost structure of clinical research services. Michael Winston drives the financial strategy for translational initiatives, ensuring that the company maintains its leadership in early-stage drug development. Through rigorous oversight, the Translational Sciences Chief Operating Officer & Chief Financial Officer supports the overall growth and scientific integrity of the organization.

Chad Clark, the President & Chief Operating Officer at Precision Medicine Group, directs the day-to-day operational execution across all service platforms. Clark oversees the scaling of internal processes to ensure that clinical research and commercialization services meet the rigorous standards of pharmaceutical clients. The President & Chief Operating Officer manages the coordination of global teams, ensuring operational efficiency across North America, Europe, and Asia-Pacific. By streamlining workflows and optimizing resource utilization, Clark drives the successful delivery of complex drug development projects. This leadership role involves constant interaction with other C-suite members to ensure that operational capacity aligns with strategic growth targets. Chad Clark maintains a focus on operational agility, allowing the company to respond rapidly to shifts in the biotech market. Through the implementation of standardized operational procedures, the President & Chief Operating Officer ensures consistent performance and high-quality service delivery.

Othniel Badea, the Chief Technology Officer at Precision Medicine Group, directs the development and implementation of advanced digital infrastructure to support clinical research and data science initiatives. Badea oversees the integration of complex genomics data and laboratory systems, ensuring that technological capabilities remain at the forefront of the life sciences industry. The Chief Technology Officer manages the deployment of scalable platforms that enable efficient drug development for global pharmaceutical clients. By fostering collaboration between data scientists and clinical researchers, Badea ensures that technological solutions directly enhance the accuracy and speed of research outcomes. This leadership role involves maintaining robust security protocols and optimizing data management systems across international operations. Othniel Badea drives the digital transformation of the company, ensuring that all technological assets support the overarching goal of accelerating the path from early-stage development to commercialization.

David Winn, the Chief Administrative Officer, Clinical Solutions at Precision Medicine Group, directs the administrative functions and organizational support structures for the clinical solutions division. Winn oversees the management of internal policies, compliance frameworks, and administrative workflows that enable the smooth operation of clinical research projects. The Chief Administrative Officer, Clinical Solutions manages the coordination of support staff and ensures that all administrative processes align with regulatory requirements. By optimizing the internal support environment, Winn allows clinical teams to focus entirely on the delivery of high-quality research services to pharmaceutical clients. This leadership role involves fostering a culture of operational efficiency and ensuring that administrative resources are effectively distributed across global projects. David Winn drives the administrative strategy for clinical solutions, ensuring that the division remains agile and responsive to client needs. Through consistent administrative oversight, the Chief Administrative Officer, Clinical Solutions supports the overall success of the company's clinical research initiatives.

Eric Hodgins, the Chief Information & Technology Officer at Precision Medicine Group, directs the enterprise-wide information technology strategy and digital security framework. Hodgins oversees the maintenance of robust IT systems that support global operations, ensuring seamless connectivity across all international offices. The Chief Information & Technology Officer manages the implementation of advanced software solutions that facilitate data sharing and collaboration between clinical research teams. By prioritizing cybersecurity and system reliability, Hodgins ensures that sensitive client data remains protected throughout the drug development process. This leadership role involves aligning IT investments with the company's long-term technological roadmap. Eric Hodgins drives the modernization of internal systems, ensuring that the organization leverages the latest digital tools to maintain a competitive advantage. Through the continuous improvement of information infrastructure, the Chief Information & Technology Officer supports the operational efficiency and data-driven decision-making capabilities of the entire company.